MEDIVATION, INC. Form 8-K: Current report
Filings on SEC EDGAR, newest first; amendments sit with their base form. Values are as filed.
- 2009-12-17: Form 8-K; Period of report 2009-12-12; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2009-12-07: Form 8-K; Period of report 2009-12-01; Description 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers; Details 5.02.
- 2009-11-06: Form 8-K; Period of report 2009-11-02; Description 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant; Details 1.01.
- 2009-11-04: Form 8-K; Period of report 2009-11-04; Description 2.02 Results of Operations and Financial Condition; Details 2.02.
| Filed | Form | Period of report | Description | Details | Document |
|---|---|---|---|---|---|
| 2009-12-17 | 8-K | 2009-12-12 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 12, 2009, the Board of Directors (the “Board”) of Medivation, Inc. (the “Company”) approved changes to the Company’s organizational structure in anticipation of the Company’s growth and transition to a commercial-stage company. | d8k.htm |
| 2009-12-07 | 8-K | 2009-12-01 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On December 1, 2009, the Compensation Committee of the Board of Directors (the “Compensation Committee”) of Medivation, Inc. (the “Company”) approved cash bonuses for the Company’s named executive officers (as defined in Item 402(a)(3) of Regulation S-K promulgated by the Securities and Exchange Commission), in recognition of both the level of the Company’s achievement of its corporate goals for 2009 and the named executive officers’ contributions toward the achievement of those goals. | d8k.htm |
| 2009-11-06 | 8-K | 2009-11-02 | 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant | 1.01 Entry into a Material Definitive Agreement. 2.03 As set forth under Item 1.01 of this Current Report on Form 8-K, on November 2, 2009, the Company entered into the Lease for the Premises. | d8k.htm |
| 2009-11-04 | 8-K | 2009-11-04 | 2.02 Results of Operations and Financial Condition | 2.02 On November 4, 2009, Medivation, Inc. (the “Company”) announced its financial results for the third quarter ended September 30, 2009. | d8k.htm |
| 2009-11-03 | 8-K | 2009-11-03 | 8.01 Other Events | 8.01 On November 3, 2009, Pfizer Inc and Medivation, Inc. issued a joint press release entitled “Pfizer And Medivation Initiate Two Phase 3 Trials Of Dimebon In Patients With Moderate-To-Severe Alzheimer’s Disease.” A copy of the joint press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. | d8k.htm |
| 2009-10-27 | 8-K | 2009-10-26 | 1.01 Entry into a Material Definitive Agreement | 1.01 Entry into a Material Definitive Agreement. | d8k.htm |
| 2009-09-23 | 8-K | 2009-09-23 | 8.01 Other Events | 8.01 On September 23, 2009, Medivation, Inc. issued a press release entitled “Medivation Announces Initiation of Phase 3 Clinical Trial of MDV3100 in Advanced Prostate Cancer.” A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. | d8k.htm |
| 2009-08-05 | 8-K | 2009-08-05 | 2.02 Results of Operations and Financial Condition | 2.02 On August 5, 2009, Medivation, Inc. (the “Company”) announced its financial results for the second quarter ended June 30, 2009. | d8k.htm |
| 2009-07-31 | 8-K | 2009-07-30 | 8.01 Other Events | 8.01 On July 30, 2009, Medivation, Inc. issued a press release entitled “Pfizer and Medivation Initiate Phase 3 Trial of Dimebon in Patients with Huntington Disease.” A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. | d8k.htm |
| 2009-06-11 | 8-K | 2009-06-11 | 8.01 Other Events | 8.01 On June 11, 2009, Medivation, Inc. issued a press release entitled “Medivation Completes Enrollment in Confirmatory, Pivotal Phase 3 ‘CONNECTION’ Trial of Dimebon in Patients with Alzheimer’s Disease.” A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. | d8k.htm |
| 2009-06-02 | 8-K | 2009-06-02 | 8.01 Other Events | 8.01 On June 2, 2009, Medivation, Inc. issued a press release entitled “Medivation Announces Positive New Efficacy Data from Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients.” A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. | d8k.htm |
| 2009-05-28 | 8-K | 2009-05-27 | 8.01 Other Events | 8.01 On May 27, 2009, Medivation, Inc. entered into an Underwriting Agreement with J. P. Morgan Securities Inc., as representative of the underwriters, relating to the sale of 2,750,000 shares of Medivation’s common stock to the underwriters, at a price per share of $19.74, which will result in approximately $54.0 million in net proceeds to the Company, after estimated expenses, and is expected to settle on June 2, 2009. | d8k.htm |
| 2009-05-27 | 8-K | 2009-05-26 | 8.01 Other Events | 8.01 On May 26, 2009 Medivation, Inc. announced that it plans to publicly offer 2,750,000 shares of its common stock pursuant to an effective registration statement previously filed with the Securities and Exchange Commission. | d8k.htm |
| 2009-05-11 | 8-K | 2009-05-11 | 2.02 Results of Operations and Financial Condition | 2.02 On May 11, 2009, Medivation, Inc. (the “Company”) announced its financial results for its first quarter ended March 31, 2009. | d8k.htm |
| 2009-03-18 | 8-K | 2009-03-12 | 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year; 8.01 Other Events | 5.03 On March 12, 2009, the Board of Directors of Medivation, Inc. (the “Company”) approved an amendment and restatement of the Bylaws (the “Bylaws”) of the Company. 8.01 On March 18, 2009, the Company issued a press release entitled “Medivation Receives FDA Permission to Initiate Phase 3 Trial of MDV3100 in Castration-Resistant Prostate Cancer.” A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. | d8k.htm |
| 2009-03-16 | 8-K | 2009-03-16 | 2.02 Results of Operations and Financial Condition | 2.02 On March 16, 2009, Medivation, Inc. (the “Company”) announced its financial results for its fourth quarter and fiscal year ended December 31, 2008. | d8k.htm |
| 2009-02-25 | 8-K | 2009-02-25 | 8.01 Other Events | 8.01 On February 25, 2009, Medivation, Inc. issued a press release entitled “Medivation Announces New Positive Efficacy Data from Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients.” A copy of the press release is attached as Exhibit 99.1 to this report and is incorporated herein by reference. | d8k.htm |
| 2009-01-20 | 8-K | 2009-01-13 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | 5.02 On January 13, 2009, the Board of Directors (the “Board”) of Medivation, Inc. (the “Company”) approved the entry into a change of control severance benefits agreement with David Hung, M.D., the Company’s Chief Executive Officer (the “CEO Agreement”), a severance benefits agreement with Rohan Palekar, the Company’s Chief Commercial Officer (the “CCO Agreement”), and a change of control severance benefits agreement with each of the Company’s other current and future executive officers, including “named executive officers,” as such term is defined by Regulation SK Item 402(a)(3), 17 C.F.R. §229.10, et. seq. | d8k.htm |